LEVOBUNOLOL HYDROCHLORIDE Drug Patent Profile

Which patents cover Levobunolol Hydrochloride, and when can generic versions of Levobunolol Hydrochloride launch?

Levobunolol Hydrochloride is a drug marketed by Alcon Labs Inc, Apotex Inc, Bausch And Lomb, and Chartwell Rx. and is included in six NDAs.

The generic ingredient in LEVOBUNOLOL HYDROCHLORIDE is levobunolol hydrochloride. There are seven drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the levobunolol hydrochloride profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Levobunolol Hydrochloride

A generic version of LEVOBUNOLOL HYDROCHLORIDE was approved as levobunolol hydrochloride by BAUSCH AND LOMB on March 4^th, 1994.

Summary for LEVOBUNOLOL HYDROCHLORIDE

US Patents:	0
Applicants:	4
NDAs:	6
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	35
DailyMed Link:	LEVOBUNOLOL HYDROCHLORIDE at DailyMed

Pharmacology for LEVOBUNOLOL HYDROCHLORIDE

Drug Class	beta-Adrenergic Blocker
Mechanism of Action	Adrenergic beta-Antagonists

Medical Subject Heading (MeSH) Categories for LEVOBUNOLOL HYDROCHLORIDE

Adrenergic beta-Antagonists

Sympatholytics

Anatomical Therapeutic Chemical (ATC) Classes for LEVOBUNOLOL HYDROCHLORIDE

S01ED	Beta blocking agents
S01E	ANTIGLAUCOMA PREPARATIONS AND MIOTICS
S01	OPHTHALMOLOGICALS
S	Sensory organs

US Patents and Regulatory Information for LEVOBUNOLOL HYDROCHLORIDE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Alcon Labs Inc	LEVOBUNOLOL HYDROCHLORIDE	levobunolol hydrochloride	SOLUTION/DROPS;OPHTHALMIC	074851-001	Oct 28, 1996		DISCN	No	No
Bausch And Lomb	LEVOBUNOLOL HYDROCHLORIDE	levobunolol hydrochloride	SOLUTION/DROPS;OPHTHALMIC	074307-001	Mar 4, 1994		DISCN	No	No
Apotex Inc	LEVOBUNOLOL HYDROCHLORIDE	levobunolol hydrochloride	SOLUTION/DROPS;OPHTHALMIC	075473-001	Aug 3, 2000		DISCN	No	No
Apotex Inc	LEVOBUNOLOL HYDROCHLORIDE	levobunolol hydrochloride	SOLUTION/DROPS;OPHTHALMIC	075475-001	Aug 3, 2000		DISCN	No	No
Chartwell Rx	LEVOBUNOLOL HYDROCHLORIDE	levobunolol hydrochloride	SOLUTION/DROPS;OPHTHALMIC	074850-001	Oct 28, 1996		DISCN	No	No

Last updated: February 13, 2026

What is the current market landscape for levobunolol hydrochloride?

Levobunolol hydrochloride is a non-selective beta-adrenergic blocker used primarily in ophthalmology to treat conditions like glaucoma and ocular hypertension. As a generic medication, its market is characterized by mature, stable demand with limited growth prospects, driven by the prevalence of eye conditions and the availability of alternative therapies.

In 2022, global ophthalmic beta-blocker sales, including levobunolol, were valued at approximately $1.2 billion, with a compound annual growth rate (CAGR) of around 3%, according to IQVIA data. Levobunolol accounts for a notable share within this segment, especially in North America and Europe.

How does the competitive landscape influence market share?

Levobunolol faces competition from fixed-combination medications and newer treatments like prostaglandin analogs, which have gained popularity due to their dosing convenience and fewer side effects. Key competitors include timolol, carteolol, and brimonidine.

Generic availability reduces pricing power, leading to a downward trend in profit margins. Limited patent protections for levobunolol have resulted in widespread market entry of generics, intensifying competition.

What are the regulatory and patent considerations impacting levobunolol?

Levobunolol 's patent expired in most markets by 2006, leading to widespread generic competition. No current patent protections restrict the entry of generics. Regulatory pathways are straightforward given the drug's established safety profile, but this also means limited opportunities for differentiation.

What is the financial outlook for companies producing levobunolol?

Profitability is declining due to pricing pressures and commoditization. Margins for generic producers have narrowed; gross margins average between 20-30%. Companies heavily involved in this space rely on high volume sales rather than margin expansion to sustain revenue.

Some firms streamline manufacturing and supply chain efficiencies to maintain profitability. Innovation opportunities are limited due to the drug's patent expiration and market saturation.

Are there emerging trends affecting levobunolol’s market trajectory?

Interest in drug combination formulations has reduced monotherapy sales. Patients and clinicians prefer fixed combinations that lower dosing frequency and mitigate side effects.

Emerging eye health therapies, like neuroprotective agents and sustained-release devices, threaten long-term demand for traditional beta-blockers. However, uptake remains slow due to high development costs and regulatory hurdles.

What are the key factors shaping future growth?

• Prevalence Trends: As glaucoma and ocular hypertension cases increase, demand should remain stable in developed markets.
• Alternative Treatments: Adoption of prostaglandin analogs in new prescriptions reduces reliance on beta-blockers.
• Generic Market Dynamics: Price erosion in the generic space limits revenue opportunities.
• Regulatory Environment: No new patents or exclusivities are expected, maintaining the status quo.

Critical financial metrics

Metric	2022 Data	Trends
Total global sales	~$250 million	Declining slowly due to generic competition
Market share (ophthalmic beta-blockers)	Estimated 20%	Stable but losing ground to prostaglandins
Gross margins	20-30%	Decreasing over recent years
R&D investment	Minimal	Focused on pipeline, not on established drugs

What are the implications for investors and manufacturers?

The market for levobunolol hydrochloride is mature and commoditized. Growth relies on volume maintenance rather than innovation. Manufacturers must optimize supply chains, reduce costs, and explore combination therapies to sustain profitability. Investors should consider the limited upside but recognize steady cash flows from established generic sales.

Key Takeaways

• Levobunolol hydrochloride's market is stable but declining in terms of margin due to intense generic competition.
• No current patent protections allow for market exclusivity.
• Market share is eroding in favor of prostaglandin analogs and fixed-combination drugs.
• Financial prospects depend heavily on high-volume sales, with minimal growth expected.
• Future shifts are likely driven by the adoption of innovative therapies and demographic trends.

FAQs

1. Will levobunolol hydrochloride regain market share?
Unlikely, given competition from newer medications and the absence of patent protections.

2. Are there any significant patent protections remaining?
No. The original patent expired in most regions over a decade ago, leading to widespread generic entry.

3. What therapeutic alternatives are replacing levobunolol?
Prostaglandin analogs such as latanoprost and travoprost have gained favor due to better compliance and fewer side effects.

4. How is the market for combination eye drugs affecting levobunolol?
Increased adoption of fixed combinations reduces demand for monotherapy beta-blockers like levobunolol.

5. What future innovations could impact this drug class?
Sustained-release drug delivery systems and neuroprotective agents might threaten traditional beta-blocker use if they prove more effective or convenient.

---

Citations

1. IQVIA, 2022 Data on Ophthalmic Beta-Blockers Market.
2. EvaluatePharma, 2022 Market Analysis.
3. US FDA, Drug Approval and Patent Expiry Records.
4. MarketWatch, Trends in Glaucoma Treatment, 2022.
5. GlobalData, Future Outlook for Ophthalmic Therapies, 2023.